IDXX · Intrinsic value
Is IDEXX Laboratories, Inc. (IDXX) overvalued or undervalued?
IDEXX Laboratories, Inc. (IDXX) trades at the delayed market price of $556.48 a share. That price already implies revenue growth of more than 25%/yr. TickerWorth's fair value is $244.30 a share (128% above fair value), as of Oct 19, 2026. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is IDXX overvalued?
- Fair value
- $244.30
- Market price
- $556.48
- Downside to fair value
- 56.1%
- Verdict
- 128% above fair value
Reverse DCF: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is IDXX's TickerWorth Score?
Far above our estimate — the business scores well
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: trades above our estimate of what it's worth.
- Value · 23 of 100
Cheaper than 23% of Healthcare companies in US
- Price vs worth · 5 of 100
- Quality · 82 of 100
More profitable than 82% of Healthcare companies in US
- Financial health · 39 of 100
Financially stronger than 39% of Healthcare companies in US
- Growth · 44 of 100
Growing faster than 44% of Healthcare companies in US
- Momentum · 31 of 100
Outperformed 31% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
IDXX DCF valuation: what the price assumes
At a recent price of $556.48, IDEXX Laboratories, Inc. (IDXX) trades 128% above TickerWorth's blended fair value of $244.30 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices IDXX overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -56.1% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values IDXX at about $155.96 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts IDEXX Laboratories, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 12.3%, with a long-run terminal growth rate of 2.5%. About 64% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — IDXX would need sustained revenue growth of more than 25%/yr to justify today's price, against about 6.9% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, IDXX's modeled DCF value ranges from about $127.14 to $204.14 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what IDEXX Laboratories, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of IDXX's intrinsic value. Figures update as new filings and prices come in.
Every input behind IDXX's DCF
| Input | Value |
|---|---|
| Base-year revenueIDEXX LABORATORIES INC /DE FY2025 10-K (accession 0000874716-26-000038): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $4,303,700,000 |
| Base EBIT marginIDEXX LABORATORIES INC /DE FY2025 10-K (accession 0000874716-26-000038): us-gaap:OperatingIncomeLoss 1,360,031,000 / revenue 4,303,702,000 = 31.60%, FY2025. | 31.6% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 10% → 8% → 7% → 5% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.54 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesIDEXX LABORATORIES INC /DE FY2025 10-K (accession 0000874716-26-000038): WeightedAverageNumberOfDilutedSharesOutstanding = 81,025,000 shares, FY2025. | 81M |
| Market priceDelayed quote · as of 2026-10-19 16:21 UTC | $556.48 |
Change IDXX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does IDEXX Laboratories, Inc. do?
What does it do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in United States. The company employs roughly 11,000 people.
How does it make money?
The business turns $4.6B in annual revenue into profit. Out of every $100 of sales, about $35 is left as operating profit (operating margin of 35.0%), after a 62% gross margin on the products/services it sells. After all costs, taxes and interest, 25.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.7× equity), can just cover its short-term bills (1.2× current ratio), and is currently profitable.
Who at IDXX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Kingsley Lawrence D | Director | Option exercise | $251,516.51 | Form 4 for Kingsley Lawrence D (opens sec.gov in a new tab) | |
| Kingsley Lawrence D | Director | Open-market sale | $1,172,177.97 | Form 4 for Kingsley Lawrence D (opens sec.gov in a new tab) | |
| Emerson Andrew | EVP, CFO and Treasurer | Option exercise | $47,238.90 | Form 4 for Emerson Andrew (opens sec.gov in a new tab) | |
| Emerson Andrew | EVP, CFO and Treasurer | Shares withheld (tax) | — | Form 4 for Emerson Andrew (opens sec.gov in a new tab) | |
| HOOLEY JOSEPH L | Director | Grant / award | $27,381.20 | Form 4 for HOOLEY JOSEPH L (opens sec.gov in a new tab) | |
| FENNELL GEORGE | Executive Vice President | Option exercise | — | Form 4 for FENNELL GEORGE (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is IDXX's intrinsic value?
TickerWorth's blended fair value for IDEXX Laboratories, Inc. (IDXX) is $244.30 per share, versus a market price of $556.48 (128% above fair value).
Is IDXX overvalued or undervalued?
On our blended fair value IDXX looks overvalued vs fair value at $556.48. This is an educational estimate, not advice.
What discount rate is used for IDXX?
A WACC of 12.3% and a terminal growth rate of 2.5%.
Is IDEXX Laboratories stock undervalued?
TickerWorth's fair value for IDEXX Laboratories, Inc. (IDXX) is $244.30 against a market price of $556.48. Our read: 128% above fair value. This is a model estimate, not investment advice.
IDEXX Laboratories (IDXX) DCF valuation and fair value
Our fair value for IDEXX Laboratories, Inc. (IDXX) is $244.30, built on a 12.3% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into IDEXX Laboratories stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $556.48. A model estimate, not investment advice.
IDEXX Laboratories (IDXX) insider trading
The most recent insider filing (SEC Form 4) for IDEXX Laboratories, Inc. (IDXX): Kingsley Lawrence D, Director, option exercise on 2026-09-04. The latest filings are listed on this page. A disclosure, not a signal to trade.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.